Northern Trust
VRPX

Northern Trust’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Northern Trust’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-61
Closed -$4.87K – 4519
2023
Q4 		$4.87K Hold
61
– – ﹤0.01% 4454
2023
Q3 		$12.2K Hold
61
– – ﹤0.01% 4385
2023
Q2 		$16.4K Hold
61
– – ﹤0.01% 4435
2023
Q1 		$11.9K Hold
61
– – ﹤0.01% 4505
2022
Q4 		$9.47K Hold
61
– – ﹤0.01% 4581
2022
Q3 		$18K Hold
61
– – ﹤0.01% 4567
2022
Q2 		$26K Hold
61
– – ﹤0.01% 4584
2022
Q1 		$34K Hold
61
– – ﹤0.01% 4601
2021
Q4 		$52K Buy
+61
New +$62.8K ﹤0.01% 4586

Other funds holding VRPX

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SRCM
Signature Resources Capital Management Newport Beach, California $254M AUM 26.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Northern Trust's VRPX Position: Q1 2024 in Review

Northern Trust sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2024, closing a stake of 61 shares — an estimated $4.87K sold.

Northern Trust first reported a position in VRPX in Q4 2021 and held it in 9 quarters. The position peaked at $52K in Q4 2021. 3 funds tracked by Wall St. Rank hold VRPX as of Q1 2024.

  • Northern Trust reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Northern Trust sold 61 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $4.87K.
  • Northern Trust first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Northern Trust's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $52K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Northern Trust's 13F filing for Q1 2024, filed 14 May 2024.